Ribociclib Production Cost Reports

The report provides a detailed analysis essential for establishing a Ribociclib production plant. It encompasses all critical aspects necessary for Ribociclib production, including the cost of Ribociclib production, Ribociclib plant cost, Ribociclib production costs, and the overall Ribociclib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Ribociclib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ribociclib is an inhibitor that is used for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is used in combination with an aromatase inhibitor like letrozole as first-line endocrine therapy or with fulvestrant following endocrine progression. It is approved for adjuvant therapy in high-risk stage II and III early breast cancer with an aromatase inhibitor to lower recurrence risk. It works by blocking cyclin-dependent kinases 4 and 6 to arrest cancer cell division in the G1 phase of the cell cycle.

It improves endocrine therapies' efficacy in postmenopausal women, men, or premenopausal women receiving LHRH agonists. Its common side effects include low white blood cell counts (neutropenia, leukopenia), elevated liver enzymes, fatigue, nausea, diarrhoea, hair thinning or loss, headache, etc.

The market for Ribociclib is driven by breast cancer cases globally. Its utilisation in HR+ and HER2 types in postmenopausal women who need targeted therapies contributes to its demand. Its usage as a personalised option and expanded approvals from metastatic to early-stage adjuvant boosts its demand. Also, ongoing R&D into new combinations like hormone therapies, and strong clinical efficacy from trials make it a popular drug.

The industrial Ribociclib procurement is influenced by limited GMP-certified API suppliers requiring USDMF and CEP filings and on-site audits. Also, the heavy reliance on imports, vulnerable to geopolitical tensions, sanctions, or raw material shortages, affects its sourcing. Other factors, like high quality and R&D costs for purity in complex synthesis and competition from palbociclib and abemaciclib impacts its market dynamics.

Raw Material for Ribociclib Production

According to the Ribociclib production plant project report, the key raw materials used in the production of Ribociclib include 2,6-dichloro-5-bromopyrimidine and Cyclohexylamine.

Production Process of Ribociclib

The extensive Ribociclib production cost report consists of the following major industrial production process:

1. From 2,6-Dichloro-5-Bromopyrimidine: The production of Ribociclib involves multiple steps. First, 2,6-dichloro-5-bromopyrimidine and cyclohexylamine go through an initial nucleophilic substitution on the pyrimidine ring. This is followed by C–C/C–N coupling, intramolecular cyclisation, and oxidative amidation to install the amide framework. After that, substitution takes place to introduce the morpholinyl and aminopiperidinyl fragments. Finally, hydrolysis takes place to give Ribociclib.

Ribociclib appears as a slightly hygroscopic yellow to brown crystalline powder. It is formulated as its succinate salt with the molecular formula C23H30N8O (free base) and molecular weight of 434.55 g/mol. It is soluble in aqueous acids, which enables tablet formulation.  It has a hydrogen bond donor count of 4, an acceptor counts of 9, rotatable bonds of 5, and a topological polar surface area that supports its oral bioavailability. It has a pyrrolo[2,3-d]pyrimidine core fused with a cyclopentyl substituent, piperazine-linked pyridine, and a dimethylamide group that helps in CDK4/6 binding via interaction with the kinase ATP site.